(UNH) UnitedHealth - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US91324P1021
UNH: Health, Insurance, Pharmacy, Services, Benefits, Care
UnitedHealth Group Incorporated (NYSE:UNH) is a prominent player in the healthcare sector, operating through four distinct segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. This diversification strategy underscores the companys resilience and adaptability in a dynamic industry.
The UnitedHealthcare segment is the backbone of the company, offering a wide array of health benefit plans and services. It caters to a diverse clientele, including national employers, public sector entities, and individuals, with a particular focus on those aged 50 and older. This segment also addresses the needs of Medicaid recipients and underserved populations, enhancing its market reach and social impact.
Optum Health focuses on care delivery and management, integrating wellness programs and financial services to create a holistic approach to healthcare. This segments comprehensive services are designed to improve patient outcomes and streamline care systems, making it a valuable asset for both providers and payers.
Optum Insight leverages technology and consulting expertise to support healthcare organizations. By offering software solutions and advisory services, this segment helps clients optimize their operations and decision-making processes, driving efficiency in the healthcare ecosystem.
Optum Rx provides pharmacy care services, emphasizing convenience and cost-effectiveness through retail networks and home delivery options. This segment also focuses on disease management and drug adherence programs, enhancing patient care while controlling costs.
Founded in 1974 and headquartered in Minnesota, UnitedHealth Group has established itself as a stable and innovative leader in healthcare. Its strategic diversification across various healthcare sectors positions it well for sustained growth and adaptability
Additional Sources for UNH Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
UNH Stock Overview
Market Cap in USD | 462,369m |
Sector | Healthcare |
Industry | Healthcare Plans |
GiC Sub-Industry | Managed Health Care |
IPO / Inception | 1984-10-26 |
UNH Stock Ratings
Growth 5y | 72.8% |
Fundamental | 52.2% |
Dividend | 65.2% |
Rel. Strength Industry | -11.3 |
Analysts | 4.63/5 |
Fair Price Momentum | 472.83 USD |
Fair Price DCF | 519.88 USD |
UNH Dividends
Dividend Yield 12m | 1.64% |
Yield on Cost 5y | 3.17% |
Annual Growth 5y | 11.11% |
Payout Consistency | 95.0% |
UNH Growth Ratios
Growth Correlation 3m | -37.9% |
Growth Correlation 12m | 56.6% |
Growth Correlation 5y | 87.7% |
CAGR 5y | 12.54% |
CAGR/Max DD 5y | 0.39 |
Sharpe Ratio 12m | -0.36 |
Alpha | -15.11 |
Beta | 0.05 |
Volatility | 31.68% |
Current Volume | 19864.9k |
Average Volume 20d | 4652.7k |
As of February 22, 2025, the stock is trading at USD 466.42 with a total of 19,864,874 shares traded.
Over the past week, the price has changed by -10.91%, over one month by -11.16%, over three months by -21.64% and over the past year by -9.24%.
Partly, yes. Based on ValueRay Fundamental Analyses, UnitedHealth (NYSE:UNH) is currently (February 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 52.24 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of UNH as of February 2025 is 472.83. This means that UNH is currently overvalued and has a potential downside of 1.37%.
UnitedHealth has received a consensus analysts rating of 4.63. Therefor, it is recommend to buy UNH.
- Strong Buy: 19
- Buy: 6
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, UNH UnitedHealth will be worth about 510.7 in February 2026. The stock is currently trading at 466.42. This means that the stock has a potential upside of +9.49%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 637.2 | 36.6% |
Analysts Target Price | 636.8 | 36.5% |
ValueRay Target Price | 510.7 | 9.5% |